-- AlphaValue/Baader Europe on Monday upgraded biopharmaceutical company UCB (UCB.BR) to reduce from sell and decreased its price target to 225 euros from 234 euros.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)